 The FDA has signed off Investigational Device Exemption IDE AcQBlate AF trial for Acutus Medical Incs NASDAQ: AFIB AcQBlate Force Sensing Ablation Catheter and System. The trial is expected to enroll 350 subjects and evaluate the systems safety and efficacy in the treatment of both paroxysmal and persistent atrial fibrillation. 